A discovery has provided significant insight into the overall genome structure of dinosaurs.
Our ability to reconstruct physical features from DNA is advancing, but can we ensure the privacy of “anonymised” genetic data if we can predict the face of its owner?
The U.K. Prime Minister, Theresa May has made her first appearance in a series on industrial strategy, whereby she has pledged millions of pounds of government funding to develop artificial intelligence to transform outcomes through early diagnosis of cancer and chronic disease.
A new way to simplify complex biomolecular data about tumours could in principle make it easier to prescribe the appropriate treatment for a specific patient.
Illumina has revealed that it has acquired Edico Genome, with the intention of building on the solid foundation of DRAGEN, to deliver a more streamlines sample for customers.
Researchers have developed a new technique for the powerful gene editing tool CRISPR to restore retinal function in mice afflicted by a degenerative retinal disease. This is the first time researchers have successfully applied CRISPR technology to a type of inherited disease known as a dominant disorder.
Participants covering all aspects of science met at this year’s Genome-Project-write, to discuss how they were going to construct an entire genome from scratch.
A bit of advice for any criminals inspired to try and edit their own genes – it’s unlikely to work, and it may present health risks.
Most people don’t like going to the doctor. That’s why Theodoros Zanos, a researcher at The Feinstein Institute for Medical Research, is working on a technology that might one day be able to listen to, and decode the body’s electrical signals, catching warning signs of illness.
The Allen Institute for Cell Science has launched the first predictive and comprehensive, 3D model of a live human cell.
The funds will be used to support the next phase in creating Luna DNA’s genomic and medical research platform and enlisting data contributors.
Under the settlement agreement, Oxford Nanopore will refrain from offering its 2D sequencing products in the UK and Germany through the end of 2023.